CTLA4 and lung cancer: Notably, Maprotiline, identified as a PD-L1 regulator through SPOP targeting, has demonstrated synergistic efficacy with anti-CTLA4 therapy in preclinical models of colorectal and lung cancer, underscoring its translational potential 46.